Skip to content

Pharmacy

CVS Health expands initiatives to fight opioid abuse in Maryland

CVS Health expands initiatives to fight opioid abuse in Maryland

As part of CVS Health’s national commitment to address and prevent opioid abuse and misuse, the company has installed 19 safe medication disposal units in CVS Pharmacy locations across Maryland and the CVS Health Foundation has provided $85,000 to Total Health Care in Baltimore, a community health c

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s Laboratories announced the launch of hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) tablets, in the U.S. market, approved by the U.S. Food and Drug Administration. The Plaquenil brand and generic had U.S.

Avella’s use of AdhereTech improves adherence

Avella’s use of AdhereTech improves adherence

Avella Specialty Pharmacy’s Use of AdhereTech smart pill bottles improved adherence and generated one to two additional fills per patient per year across multiple specialty medications and diseases The specialty pharmacy uses the smart bottles for five specialty medications, in programs with four di

McKesson highlights power of community pharmacy in Vegas

McKesson highlights power of community pharmacy in Vegas

McKesson ideaShare 2018, McKesson Corporation’s annual interactive forum for community pharmacists, kicked off today in Las Vegas. The annual event offers those in community pharmacy the opportunity to improve their knowledge, performance and profitability while networking with industry experts.

Catalent agrees to buy Juniper Pharmaceuticals

Catalent agrees to buy Juniper Pharmaceuticals

SOMERSET, N.J. – Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division.

Dermira gets FDA approval for Qbrexza cloth

Dermira gets FDA approval for Qbrexza cloth

Dermira announced that the U.S. Food and Drug Administration (FDA) has approved Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.